留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

肿瘤靶向纳米递释系统存在问题的分析

李文清 邹豪 钟延强

李文清, 邹豪, 钟延强. 肿瘤靶向纳米递释系统存在问题的分析[J]. 药学实践与服务, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
引用本文: 李文清, 邹豪, 钟延强. 肿瘤靶向纳米递释系统存在问题的分析[J]. 药学实践与服务, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
LI Wenqing, ZOU Hao, ZHONG Yanqiang. Analysis of problems on tumor-targeting drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
Citation: LI Wenqing, ZOU Hao, ZHONG Yanqiang. Analysis of problems on tumor-targeting drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003

肿瘤靶向纳米递释系统存在问题的分析

doi: 10.3969/j.issn.1006-0111.2015.02.003

Analysis of problems on tumor-targeting drug delivery system

  • 摘要: 目的 探究目前肿瘤靶向纳米递释系统存在的问题。 方法 在全面搜集查阅有关文献的基础上, 对肿瘤靶向纳米递释系统研究现状进行归纳整理。 结果 从3个方面对肿瘤靶向纳米递释系统存在的问题以及新的发展趋势提出建议与对策。 结论 要在研究中取得突破, 需要对人体生理学及肿瘤生物学进行深入研究, 并在现有的给药策略和实验方法等方面进行调整。
  • [1] 傅刘鹏,徐 俊,黄思超,等. 叶酸脂质体对乳腺癌4T1细胞的体内靶向性研究[J].山东医药, 2010,50(7):23-25.
    [2] 高 芸,李少一,商雪莹,等. FAT10过表达对肝癌细胞HepG2侵袭及迁移能力的影响[J].实用预防医学, 2013,20(5):517-520.
    [3] Giovanna D, Maurizio D. Contemporary pre-clinical development of anticancer agents-What are the optimal preclinical models?[J].Eur J Cancer,2009,45(16):2768-2781.
    [4] Lu W, Xiong C, Zhang R, et al.Receptor-mediated transcytosis: a mechanism for active extravascular transport of nanoparticles in solid tumors[J]. J Control Release,2012, 161(3): 959-966.
    [5] Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities[J].J Control Release, 2010,141(3): 265-276.
    [6] Yoo HS,Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles[J]. J Control Release, 2004,96(2): 273-283.
    [7] Chung YI,Kima JC,Kim YH,et al.The effect of surface functionalization of PLGA nanoparticles by heparin-or chitosan-conjugated Pluronie on tumor targeting[J].J Control Release,2010,143(3):374-382.
    [8] Kirpotin DB,Drummond DC, Shao Y,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models[J].Cancer Res,2006,66(13): 6732-6740.
    [9] Rooy I, Mastrobattista E, Storm G, et al. Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain[J]. J Control Release, 2011,150(1): 30-36.
    [10] Bareford LM, Swann PW. Endocytic mechanisms for targeted drug delivery[J]. Adv Drug Deliv Rev, 2007,59(8) :748-758.
    [11] Paulos CM,Reddy JA, Leamon CP, et al. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery[J]. Mol Pharmacol, 2004,66(6): 1406-1414.
    [12] Smet M, Heijman E, Langereis S,et al. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof of concept study[J].J Control Release, 2011,150(1): 102-110.
    [13] Chen H, Kim S, He W, et al. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo Forster resonance energy transfer imaging[J]. Langmuir, 2008,24(10): 5213-5217.
    [14] Chen H, Kim S, Li L, et al. Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Forster resonance energy transfer imaging[J]. Proc Natl Acad Sci USA, 2008,105(18): 6596-6601.
    [15] Koo AN, Min KH, Lee HJ, et al.Tumor accumulation and antitumor efficacy of docetaxel-loaded core-shell-corona micelles with shell-specific redox-responsive cross-links[J]. Biomaterials, 2012,33(5): 1489-1499.
    [16] Ishida T, Ichihara M, Wang X, et al. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes[J]. J Control Release, 2006,115(3): 243-250.
    [17] Lu W,Wan J,She Z,et al.Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle[J].J Control Release,2007,118(1):38-53.
    [18] Park K. To PEGylate or not to PEGylate, that is not the question[J]. J Control Release, 2010,142(2): 147-148.
    [19] Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy[J]. Biochem Pharmacol, 2010,80(5): 762-770.
    [20] Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells[J]. Cancer Res, 2006,66(2): 1033-1039.
    [21] Netti PA, Berk DA, Swartz M A,et al. Role of etracellular matrix assembly in interstitial transport in solid tumors[J]. Cancer Res, 2000,60(9): 2497-2503.
    [22] Brown E, Mckee TD, Tomaso ED, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation[J]. Nat Med, 2003,9(6): 796-800.
    [23] Ramanujan S, Pluen A, Mckee TD, et al. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium[J]. Biophys J, 2002,83(3): 1650-1660.
    [24] Alexandrakis G, Brown E, Tong RT, et al. Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors[J]. Nat Med, 2004,10(2): 203-207.
    [25] Ernsting MJ, Murakami M, Roy A, et al. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles[J]. J Control Release, 2013,172(3): 782-794.
    [26] Damia G, D'Incalci M. Contemporary pre-clinical development of anticancer agents-what are the optimal preclinical models[J]. Eur J Cancer, 2009,45(16): 2768-2781.
  • [1] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
  • 加载中
计量
  • 文章访问数:  2181
  • HTML全文浏览量:  193
  • PDF下载量:  657
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-01-14
  • 修回日期:  2014-09-23

肿瘤靶向纳米递释系统存在问题的分析

doi: 10.3969/j.issn.1006-0111.2015.02.003

摘要: 目的 探究目前肿瘤靶向纳米递释系统存在的问题。 方法 在全面搜集查阅有关文献的基础上, 对肿瘤靶向纳米递释系统研究现状进行归纳整理。 结果 从3个方面对肿瘤靶向纳米递释系统存在的问题以及新的发展趋势提出建议与对策。 结论 要在研究中取得突破, 需要对人体生理学及肿瘤生物学进行深入研究, 并在现有的给药策略和实验方法等方面进行调整。

English Abstract

李文清, 邹豪, 钟延强. 肿瘤靶向纳米递释系统存在问题的分析[J]. 药学实践与服务, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
引用本文: 李文清, 邹豪, 钟延强. 肿瘤靶向纳米递释系统存在问题的分析[J]. 药学实践与服务, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
LI Wenqing, ZOU Hao, ZHONG Yanqiang. Analysis of problems on tumor-targeting drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
Citation: LI Wenqing, ZOU Hao, ZHONG Yanqiang. Analysis of problems on tumor-targeting drug delivery system[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(2): 106-109,170. doi: 10.3969/j.issn.1006-0111.2015.02.003
参考文献 (26)

目录

    /

    返回文章
    返回